Prostate cancer (PCa) is the most common cancer among men in Europe and the third most common cause of cancer death in European men [1]. Screening by Prostate Antigen Test (PSA) in combination with MRI has shown potential in identifying clinically significant PCa [2–4]. It is reasonable to anticipate that the demand for MRI could increase further when screening programs are established. These advances led the European Union in December 2022 to recommend (‘recommendation 2′) to test and evaluate …